GlassScriptPhysician profile
Brandon D Simon-Davis
NPI 1841496718
$3,794.36
in general payments reported to CMS, 2019-2025
31 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,228 · 2020: $1,137 · 2021: $16.57 · 2023: $136 · 2024: $107 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $568.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $496.56 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $383.52 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.96 | 2019-2020 | |
| Lilly USA, LLC | $297.16 | 2019-2020 | |
| Allergan, INC. | $284.09 | 2019-2020 | |
| Pfizer INC. | $214.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.63 | 2019 | |
| Astellas Pharma US INC | $175.43 | 2019-2020 | |
| Amarin Pharma, INC. | $129.72 | 2019-2020 | |
| Dexcom, INC. | $120.92 | 2023 | Dexcom G7 Gss (161) |
| Silk Road Medical, INC. | $91.92 | 2019 | |
| Jazz Pharmaceuticals INC. | $81.99 | 2019-2020 | |
| Inspire Medical Systems, INC. | $79.53 | 2025 | Inspire |
| Abbvie INC. | $49.52 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $44.22 | 2019-2023 | Qelbree |
| Glaxosmithkline, LLC. | $35.39 | 2019-2020 | |
| Promius Pharma LLC | $29.81 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.67 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.94 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.67 | 2020 | |
| Adlon Therapeutics L.P. | $16.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.34 | 2019 | |
| Endo Pharmaceuticals INC. | $14.45 | 2019 | |
| Eisai INC. | $13.64 | 2020 | |
| Qiagen, LLC | $13.23 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.17 | 2020 | |
| Horizon Therapeutics Plc | $13.08 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.67 | 2020 | |
| Zyla Life Sciences, INC. | $11.47 | 2019 | |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Simon-Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.